Bank of America, Pfizer and others 1Analyst price-target revisions based on quarterly results
5month 27on, several analysts revised their price targets for major U.S. stocks. Bank of America and Pfizer received upgrades based on 1quarterly results, while AbbVie and Agora had their price targets changed for different reasons.
Analysts 5month 27made successive price-target revisions for major U.S. stocks on. Bank of America 1raised its price target, citing strong quarterly results. The revision reflected the assessment of a specific securities firm.
In Bank of America's assessment, Pfizer 1received a price-target upgrade based on quarterly results. The report explicitly cited strong quarterly performance as the rationale. The result reflected both the company's official announcement and the analyst's reassessment.
Piper Sandler raised AbbVie's price target, citing progress in IBD (inflammatory bowel disease) in its pipeline. The report stated that clinical and pipeline progress affects investment decisions. The company's pipeline update was cited as the basis.
In Agora’s case, Bank of America lowered its price target, citing equity losses, but maintained its Buy rating. The report mentioned the size of the equity losses and presented them as grounds for the downgrade. Since the Buy rating was also maintained, the rating itself remains unchanged.
This round of adjustments reflects analysts’ assessments of earnings, pipelines, and investment losses. Each report was issued based on information about the individual company’s disclosures, earnings, and pipeline. Investors should review the companies’ official disclosures alongside the analyst reports.
Sources: Yahoo Finance,Investing.com News
Bullstory synthesized this report from the linked sources. AI may have assisted the writing process. Check the original reports for factual confirmation.